AHFS Drug Information October 2023 Update

This update contains 11 new monographs, 22 revised monographs, and 4 new MedWatch alerts.

New monographs: Avacincaptad Pegol Sodium; Axicabtagene Ciloleucel; Cantharidin; Donislecel-jujn; Elranatamab-bcmm; Lotilaner; Nirsevimab-alip; Quizartinib Dihydrochloride; Rozanolixizumab-noli; Somatrogon-ghla; Talquetamab-tgvs.

Revised monographs: Abemaciclib; C1-Esterase Inhibitor (Human); C1-Esterase Inhibitor (Recombinant); Cabotegravir and Rilpivirine; Capmatinib Hydrochloride; Celecoxib; Dacomitinib; Deferiprone; Ebola Zaire Vaccine Live; Entrectinib; Evinacumab-dgnb; Ganaxolone; Gilteritinib Fumarate; Melphalan; Mepolizumab; Naloxone Hydrochloride; Olipudase alfa-rpcp; Omadacycline Tosylate; Pacritinib Citrate; Sodium Phenylbutyrate and Taurursodiol; Teclistamab-cqyv; Umeclidinium Bromide.

New MedWatch alerts on the following monographs: Bupivacaine Hydrochloride, Bupivacaine Liposomal; Chloroprocaine Hydrochloride; cloNIDine; Ropivacaine Hydrochlorid.